Slide background

Answering The Right Questions.

Designing The Right Molecules.

INDICATION Osteoporosis

OBJECTIVE:

Discover a novel PCC candidate with better efficacy, PK and safety profile than a competitor compound

MILESTONE:

From patent literature to First PCC Nomination within 17 months

THERAPEUTIC AREA Pain Indication

OBJECTIVE:

Discover a novel PCC candidate with better efficacy, PK and safety profile than a benchmark compound

MILESTONE:

From patent literature to First PCC Nomination within 24 months

THERAPEUTIC AREA  Antiviral

OBJECTIVE:

Discover the best-in-class compound with improved PK profiles

MILESTONE:

Discovered 4 PCCs
1st PCC advanced to Phase I
2nd PCC advanced to NDA submission

THERAPEUTIC AREA Oncology

OBJECTIVE:

Discover PCC for a novel target

MILESTONE:

14 structurally diverse scaffolds
70% of new targets designed by WuXi
PCC declared by partner